Tikcro Technologies Ltd. (TIKRF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tikcro Technologies Ltd. (TIKRF) Financial Services Profile

Tikcro Technologies Ltd., based in Israel, is a biotechnology-focused shell company specializing in the development of anti-cytotoxic T-lymphocyte-associated protein 4 for cancer immune treatment. Operating within the financial services sector, the company seeks to advance its biotechnology projects, though it currently has a limited market capitalization.

What Is the Investment Thesis for TIKRF?

Tikcro Technologies Ltd. presents a speculative investment opportunity due to its focus on developing anti-CTLA-4 therapies for cancer treatment. The potential success of its biotechnology projects is the primary value driver. However, the company's status as a shell company and its limited financial resources introduce significant risks. Key catalysts include positive preclinical or clinical trial results for its CTLA-4 program, which could attract partnerships or further investment. Conversely, failure to advance its projects or secure additional funding could negatively impact its prospects. Investors should carefully consider the high-risk, high-reward nature of this investment, given the uncertainties inherent in biotechnology development and the company's financial constraints. The negative P/E ratio of -2.27 and absence of dividends further underscore the speculative nature of this investment.

Based on FMP financials and quantitative analysis

TIKRF Key Highlights

Tikcro Technologies Ltd. operates in the Financial Services sector, specifically as a Shell Company.

• The company focuses on developing biotechnology projects in Israel, particularly anti-cytotoxic T-lymphocyte-associated protein 4 for cancer immune treatment.
• Tikcro Technologies Ltd. was founded in 1999 and is headquartered in Hadera, Israel.
• The company has a market capitalization of $1.09M, indicating a micro-cap status.
• Tikcro Technologies Ltd. has a negative P/E ratio of -2.27, reflecting its current lack of profitability.

Who Are TIKRF's Competitors?

TIKRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TIKRF's Key Strengths?

Focus on a specific area of cancer immunotherapy (CTLA-4).

• Potential for breakthrough therapies in cancer treatment.
• Location in Israel, a hub for biotechnology innovation.

What Are TIKRF's Weaknesses?

Small market capitalization and limited financial resources.

• Dependence on the success of a single technology (CTLA-4).
• High risk associated with biotechnology development.
• Shell company status adds uncertainty.

What Could Drive TIKRF Stock Higher?

Announcement of preclinical or clinical trial results for its CTLA-4 therapy.

• Securing partnerships with larger pharmaceutical companies.
• Acquisition or merger with a promising private biotechnology company.
• Progress in research and development of its biotechnology projects.
• Changes in the regulatory landscape for cancer immunotherapy.

What Are the Key Risks for TIKRF?

Financial-distress signal — its Altman Z-Score of -46.72 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-12.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
• Failure to advance its CTLA-4 therapy through clinical trials.
• Competition from other companies developing cancer immunotherapies.
• Regulatory hurdles and delays in drug approval.
• Limited financial resources and dependence on external funding.
• High risk associated with biotechnology development.

What Are the Growth Opportunities for TIKRF?

• Advancement of CTLA-4 Program: Tikcro's primary growth opportunity lies in the successful development and commercialization of its anti-CTLA-4 therapy. The global cancer immunotherapy market is projected to reach $100 billion by 2028, driven by the increasing prevalence of cancer and the demand for more effective treatments. Positive preclinical and clinical trial results could attract partnerships with larger pharmaceutical companies, providing significant funding and expertise. The timeline for this growth opportunity depends on the pace of clinical development and regulatory approvals, potentially spanning 3-5 years.
• Strategic Acquisitions or Mergers: As a shell company, Tikcro's growth is also dependent on its ability to identify and acquire or merge with a promising private biotechnology company. This could provide access to new technologies, products, and markets. The market for biotechnology acquisitions is active, with numerous deals occurring annually. A successful acquisition could significantly increase Tikcro's value and growth potential. The timeline for this opportunity is uncertain, as it depends on market conditions and the availability of suitable targets.
• Expansion of Intellectual Property Portfolio: Tikcro can pursue growth by expanding its intellectual property portfolio through the development of new therapies or technologies related to cancer immunotherapy. This could involve filing patents on novel drug targets, formulations, or delivery methods. A strong IP portfolio can provide a competitive advantage and attract licensing opportunities. The timeline for this growth opportunity depends on the pace of research and development, potentially spanning several years.
• Securing Government Grants and Funding: Tikcro can seek to secure government grants and funding to support its research and development activities. Government agencies and non-profit organizations often provide funding for innovative biotechnology projects, particularly those focused on addressing unmet medical needs. Securing such funding can reduce the company's financial risk and accelerate its progress. The timeline for this opportunity depends on the availability of grants and the success of grant applications.
• Partnerships with Research Institutions: Collaborating with leading research institutions and universities can provide Tikcro with access to cutting-edge technologies, expertise, and resources. These partnerships can accelerate the development of new therapies and expand the company's scientific capabilities. The timeline for this growth opportunity depends on the specific partnerships and the nature of the collaborative projects.

What Are TIKRF's Competitive Advantages?

• Focus on a specific area of cancer immunotherapy (CTLA-4).
• Potential intellectual property related to its anti-CTLA-4 therapy.
• Location in Israel, which has a strong biotechnology ecosystem.

What Does TIKRF Do?

Tikcro Technologies Ltd., headquartered in Hadera, Israel, was founded in 1999 as Tioga Technologies Ltd., later changing its name in September 2003. The company focuses on the development of biotechnology projects, with a specific interest in anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for cancer immune treatment. CTLA-4 is a protein receptor that downregulates the immune system. Tikcro's business model centers around identifying and developing early-stage biotechnology opportunities, primarily within Israel. As a shell company, its operations involve seeking out and potentially acquiring or merging with a private entity to bring its technology to market. The company's success is heavily dependent on the progress and eventual commercialization of its biotechnology projects. Given its focus on a specific area of cancer immunotherapy, Tikcro's competitive positioning relies on the uniqueness and efficacy of its CTLA-4 targeted therapies. The company's small market capitalization reflects its early stage and the inherent risks associated with biotechnology development.

What Products and Services Does TIKRF Offer?

• Focuses on the development of biotechnology projects in Israel.
• Specializes in anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for cancer immune treatment.
• Operates as a shell company, seeking to acquire or merge with private entities.
• Aims to bring new biotechnology technologies to market.
• Conducts research and development activities related to cancer immunotherapy.

How Does TIKRF Make Money?

• Identifies and develops early-stage biotechnology opportunities.
• Seeks to acquire or merge with private biotechnology companies.
• Aims to commercialize its biotechnology projects through partnerships or acquisitions.

What Industry Does TIKRF Operate In?

Tikcro Technologies Ltd. operates within the financial services sector as a shell company focused on biotechnology. The shell company landscape is characterized by entities seeking to acquire or merge with private companies to facilitate their public listing. This approach is often used by biotechnology companies to accelerate their entry into the public markets. The biotechnology industry itself is driven by innovation in drug development and diagnostics, with significant investment in cancer immunotherapy. Tikcro's focus on anti-CTLA-4 therapies places it within this competitive landscape, where success depends on scientific breakthroughs and regulatory approvals. Competitors in this space include both established pharmaceutical companies and smaller biotechnology firms pursuing similar immuno-oncology targets.

Who Are TIKRF's Key Customers?

• Potentially pharmaceutical companies seeking to acquire or license new therapies.
• Future patients who may benefit from the company's cancer immune treatment.
• Investors interested in the biotechnology sector.

Company Profile

Tikcro Technologies Ltd. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Hadera, IL. The company is led by CEO Aviv Boim. TIKRF has traded publicly since 2000.

How Tikcro Technologies Ltd. Is Valued

Tikcro Technologies Ltd. carries a market capitalization of $1.09M, placing it in the micro-cap category. Relative to its peer group, TIKRF's quantitative score of 44/100 is below the peer average of 60/100.

Return on equity for Tikcro Technologies Ltd. stands at -12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -46.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 20.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -44.0%, the inverse of the P/E and a quick read on earnings relative to price.

Tikcro Technologies Ltd.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -46.72 places it in the distress zone, a signal of elevated financial risk.

TIKRF Financials

TIKRF Latest News

No recent news available for TIKRF.

TIKRF Analyst Consensus

TIKRF MoonshotScore

Common Questions About TIKRF (Financial Services)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources